Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis

Magdalena Rysz-Górzynska1,2, Anna Gluba-Brzózka2,3, Amirhossein Sahebkar4,5, Maria-Corina Serban6,7, Dimitri P. Mikhailidis9, Sorin Uroniu9, Peter P. Toth10,11, Vera Bittner6, Gerald F. Watts12, Gregory Y. H. Lip13, Jacek Rysz2,3, Alberico L. Catapano14 & Maciej Banach1,2

Since the evidence regarding statin therapy in PAH has not been conclusive, we assessed the impact of statin therapy in PAH through a systematic review and meta-analysis of available studies. We searched selected databases up to August 1, 2015 to identify the studies investigating the effect of statin administration on PAH. Meta-analysis was performed using either a fixed-effects or random-effect model according to the statistic. Meta-analysis of 8 studies with 665 patients did not suggest any significant improvement in 6-min walking distance (6MWD) by statin therapy (weighed mean difference [WMD]: −6.08 m, 95% confidence interval [CI]: −25.66, 13.50, p = 0.543; Q = 8.41, I² = 28.64%). Likewise, none of the other indices including pulmonary arterial pressure (WMD: −0.97 mmHg, 95%CI: −4.39, 2.44, p = 0.577; Q = 14.64, I² = 79.51%), right atrial pressure (WMD: 1.01 mmHg, 95%CI: −0.93, 2.96, p = 0.307; Q = 44.88, I² = 95.54%), cardiac index (WMD: 0.05 L/min/m², 95%CI: −0.05, 0.15, p = 0.323; Q = 3.82, I² = 21.42%), and pulmonary vascular resistance (WMD: −1.42 dyn*s/cm², 95%CI: −72.11, 69.27, p = 0.969; Q = 0.69, I² = 0%) was significantly altered by statin therapy. In conclusion, the results of the meta-analysis did not show a statistically significant effect of statin therapy in the improvement of 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary vascular resistance.

Pulmonary hypertension (PAH) is defined according to the new 2015 Guidelines of the European Society of Cardiology (ESC) and European Respiratory Society (ERS) as an increase of the mean pulmonary arterial pressure (PAPm) above 25 mmHg at rest, assessed by right heart catheterization (RHC) and pulmonary vascular resistance (PVR) above 3 Wood units. Compared with the 2008 PAH guidelines, the new guidelines eliminated the exercise criterion, added hemodynamic parameters, and defined post-capillary PAH subgroups. The new guidelines categorized various PAH conditions into five groups: pulmonary arterial hypertension, pulmonary

1Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland. 2Healthy Aging Research Centre (HARC), Medical University of Lodz, Lodz, Poland. 3Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland. 4Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 5Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. 6Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA. 7Department of Functional Sciences, Discipline of Pathophysiology, “Víctor Babes” University of Medicine and Pharmacy, Timisoara, Romania. 8Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK. 9Department of Functional Sciences, Discipline of Public Health, “Víctor Babes” University of Medicine and Pharmacy, Timisoara, Romania. 10Preventive Cardiology, CGH Medical Center, Sterling, Illinois, USA. 11The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. 12Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia. 13University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK. 14Department of Pharmacological and Biomolecular Sciences University of Milan and IRCCS Multimedica Milano Italy. Correspondence and requests for materials should be addressed to M.B. (email: maciejbanach@aol.co.uk)
hypertension due to left heart disease, pulmonary hypertension due to lung diseases and/or hypoxia, chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions, and pulmonary hypertension with unclear and/or multifactorial mechanisms. Several prognostic factors such as right ventricular failure, higher World Health Organization functional classification (WHO FC), shorter 6-min walk distance (6MWD) and hemodynamic factors such as right atrial pressure, and brain natriuretic peptide (BNP) levels are useful for PAH prognosis. Furthermore, the American College of Chest Physicians’ CHEST Guideline suggests that the diagnosis of PAH should be made in a systematic and consistent manner with the use of a combination of WHO FC, exercise capacity, echocardiographic, laboratory and hemodynamic variables, and care should be provided by experts in the management of PAH. (Grade CB)4. However, the prognosis for patients with PAH remains poor, especially without appropriate treatment.

Current therapy for PAH is based on endothelin receptor antagonists, phosphodiesterase-5 (PDE5) inhibitors, prostacyclin analogues (prostanoids), soluble guanylate cyclase stimulators, and prostacyclin receptor (IP receptor) agonist.31 Despite the appearance of novel targets for PAH therapy tested in preclinical and clinical trials such as rituximab, endothelial progenitor cells, specific rho-kinase (ROCK) inhibitors (AT-877ER), FK506 (tacrolimus), fluoxetine, sertraline, paroxetine, barboxolone methyl, avipatid or tyrosine kinase inhibitors (nilotinib, soraenib and imatinib), the diagnosis and treatment of PAH is still difficult.32

The pleiotropic effects of statins through induction of endothelial nitric oxide (NO) expression as well as anti-inflammatory and antiproliferative mechanisms possibly confer various clinical advantages beyond the reduction of serum cholesterol levels. Since statins have been suggested as potential drugs for PAH treatment, we assessed the impact of statin therapy on multiple parameters in PAH in this systematic review and meta-analysis.

Methods
This study was designed according to the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. Due to the study design (meta-analysis) no Institutional Review Board (IRB) approval, as well as no patients’ informed consents were obtained.

Search Strategy. PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched using the following search terms in titles and abstracts (also in combination with MESH terms): (atorvastatin OR simvastatin OR rosuvastatin OR fluvastatin OR pravastatin OR pitavastatin OR lovastatin OR cerivastatin OR “statin therapy” OR statins OR statin) AND (“pulmonary arterial hypertension” OR “pulmonary hypertension” OR “pulmonary artery hypertension” OR “pulmonary hypertension” OR “pulmonary artery hypertension” OR “pulmonary vascular disease” OR “pulmonary heart disease” OR “pulmonary cardiac disease” OR PAH). The wild-card term “*” was used to increase the sensitivity of the search strategy. The literature search was limited to articles published in English. The search was limited to studies in humans. The literature was searched from inception to August 1, 2015. Two reviewers (MRG and AGB) evaluated each article independently. Disagreements were resolved by discussion with a third party (MB).

Study Selection. Original studies were included if they met the following criteria: (i) being a clinical study with either observational or interventional design, (ii) recruiting patients with a clinical diagnosis of PAH according to echocardiography regardless of the etiology (congenital heart disease, connective tissue disease, chronic thromboembolism or iatrogenic), and, (iii) investigating the impact of statin therapy on a valid disease activity index including 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary vascular resistance.

Exclusion criteria were: (i) non-clinical studies, (ii) lack of a statin-free control group in the study design, and, (iii) lack of sufficient information on baseline or follow-up indices of PAH.

Data extraction. Eligible studies were reviewed and the following data were abstracted: 1) first author’s name 2) year of publication 3) study location 4) study design 5) number of participants in the statin and groups 5) age, gender and body mass index (BMI) of study participants 6) type and duration of statin therapy and 7) baseline and follow-up values of PAH-related indices.

Data extraction was performed independently by 2 reviewers; disagreements were resolved by a third reviewer.

Quality assessment. Methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). In this context, topic items of each eligible study are assessed: that is, the selection of the studied patients, the comparability of the studied populations and the ascertainment of the exposure. A study can be awarded a maximum of one point for each item. Risk-of-bias assessment was performed independently by 2 reviewers; disagreements were resolved by a third reviewer.

Quantitative Data Synthesis. Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ). Net changes in measurements (change scores) were calculated as follows: measure at end of follow-up − measure at baseline. For single-arm cross-over trials, net change in each efficacy measure was calculated by subtracting the value after control intervention from that reported after treatment. Standard deviations (SDs) of the mean difference were calculated using the following formula: $SD = \sqrt{SD_{pre-treatment}^2 + (SD_{post-treatment})^2 - 2R \times SD_{pre-treatment} \times SD_{post-treatment}}$, assuming a correlation coefficient (R) = 0.5. If the outcome measures were reported in median and range or 95% CI, mean and standard SD values were estimated using the method described by Wan et al. Where standard error of the mean (SEM) was only reported, SD was estimated using the following formula: $SD = SEM \times \sqrt{n}$, where $n$ is the number of subjects.

A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used to compensate for the heterogeneity of studies in terms of demographic characteristics of populations being studied and also differences in study design and type of statin being studied. Heterogeneity was quantitatively assessed using the I² statistic.
assessed using $I^2$ index. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using leave-one-out method, i.e. removing one study each time and repeating the analysis.

**Publication bias.** Potential publication bias was explored using visual inspection of Begg's funnel plot asymmetry, Begg's rank correlation, and Egger's weighted regression. Duval and Tweedie "trim and fill" was used to adjust the analysis for the effects of publication bias.

**Results**

**Flow and characteristics of included studies.** On the basis of a database search 859 published studies were found, 310 of which were non-clinical or review articles and thus they were not included in further analysis. We screened 549 articles but 533 of them were excluded because they did not meet inclusion criteria. Out of 16 eligible papers, 6 were excluded since they were not conducted in subjects with PAH, one of them did not assess any of the pre-specified efficacy measures, and one was not a clinical study. Finally, we included 8 articles in this meta-analysis (Fig. 1).

Most of the analyzed studies (7/8) were randomized, double- or triple-blind and placebo-controlled. This meta-analysis comprised 665 patients with PAH receiving either statins (rosuvastatin, simvastatin, pravastatin or atorvastatin) (311 patients) or placebo (354 patients) for 6 months. In analyzed patients, PAH was idiopathic, heritable, associated with congenital heart disease, atrial-septal defects or connective tissue disease, and many of them suffered from chronic obstructive pulmonary disease. The PAH-related indices 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary vascular resistance were measured in 6, 6, 2, 4 and 2 analyzed studies, respectively (Table 1).

**Risk of bias assessment.** The quality of the included studies assessed by the Newcastle-Ottawa Scale (NOS) is shown in Table 2.

**Effect of statin therapy on PAH-related indices.** Meta-analysis of included studies did not suggest any significant improvement in 6MWD by statin therapy (WMD: $-6.08$ m, 95% CI: $-25.66$, 13.50, $p = 0.543$; Q = 8.41, $I^2 = 28.64$%) (Fig. 2A). This effect was robust in sensitivity analysis and the statistical significance was not influenced by any single study included in the meta-analysis (Fig. 2B). Likewise, none of the other indices including pulmonary arterial pressure (WMD: $-0.97$ mmHg, 95% CI: $-4.39$, 2.44, $p = 0.577$; Q = 14.64, $I^2 = 79.51$%) (Fig. 3A), right atrial pressure (WMD: $1.10$ mmHg, 95% CI: $-0.93$, 2.96, $p = 0.307$; Q = 44.88, $I^2 = 95.54$%) (Fig. 3B), cardiac index (WMD: $0.05$ L/min/m$^2$, 95% CI: $-0.05$, 0.15, $p = 0.323$; Q = 3.82, $I^2 = 21.42$%) (Fig. 3C), and pulmonary vascular resistance (WMD: $-1.42$ 1.42 dynes/s/cm$^5$, 95% CI: $-72.11$, 69.27, $p = 0.969$; Q = 0.69, $I^2 = 0$%) (Fig. 3D) was significantly altered by statin therapy.

**Publication bias.** The funnel plot of the study standard error by effect size (mean difference) for the meta-analysis of statin effects on 6MWD was asymmetric suggesting a potential publication bias (Fig. 4). Using “trim and fill” correction, two potentially missing studies were imputed on the left side of funnel plot, yielding an effect size of $-11.72$ m (95% CI: $-31.27$, 7.82). The results of Begg’s rank correlation (Kendall’s Tau with continuity correction = 0.38, $z = 1.20$, two-tailed $p$-value = 0.230) and Egger’s linear regression (intercept = 1.97, standard error = 1.25; 95% CI = $-1.24$, 5.18, $t = 1.58$, df = 5, two-tailed $p = 0.176$) tests excluded the possibility of publication bias in the meta-analyses.
| First author's name | Barreto et al. 17 | Kawut et al. 18 | Lee et al. 19 | Liu et al. 20 | Moosavi et al. 21 | Reed et al. 22 | Wilkins et al. 23 | Zeng et al. 24 |
|---------------------|------------------|----------------|-------------|--------------|----------------|--------------|----------------|----------------|
| Year of publication | 2008             | 2011           | 2009        | 2013         | 2013           | 2011         | 2010           | 2012           |
| Study location      | Brazil           | USA            | Taiwan      | China        | Iran           | USA          | Germany        | China          |
| Study design        | Randomized, double-blind, placebo-controlled study | 4-center, randomized, double-blind, placebo-controlled study | Randomized, double-blind, placebo-controlled trial | Randomized, placebo-controlled trial | Randomized, triple-blind, parallel-group trial | Cohort, retrospective, cross-sectional, non-randomized | Randomized, double-blind, placebo-controlled trial | Randomized, double-blind and placebo-controlled trial |
| Inclusion criteria  | Idiopathic or congenital heart disease-associated PAH (WHO functional class I–III) in the absence or presence of hypoxemia with a mean PAP > 30 mmHg at rest. Pts. > 18 years of age with PAH (WHO functional class I–III). | COPD patients at age between 40 and 80 years with PAH, provided conditions were stable for at least 3 months. | 60 to 85 years of age; in the stable chronic pulmonary heart disease with FEV1 ≤ 65% of the predicted value, the ratio of FEV1 to the forced vital capacity was < 70% and PAH was > 30 mmHg; and NYHA class I or II. | PAP > 40 mmHg, able to doing 6-MWD test, obstructive pattern in PFT and functional NYHA class II or III. | COPD patients evaluated for lung transplantation with PAH with mean PAP at rest > 25 mmHg. | Stable patients with class II or III PAH with mean PAP at rest > 25 mm Hg, pulmonary capillary wedge pressure < 15 mmHg and pulmonary vascular resistance > 3 Wood units; with a 6-MWD between 150–500 m at entry. | 18–65 years of age pts. with Class I PAH defined as mean PAP > 25 mmHg, pulmonary capillary wedge pressure < 15 mmHg and pulmonary vascular resistance > 3 Wood units. |
| Number of participants in the statin group | 30 | 32 | 27 | 33 | 24 | 34 | 19 | 112 |
| Number of participants in the placebo group | 30 | 33 | 26 | 35 | 21 | 78 | 23 | 108 |
| Age of statin group | 34.6 ± 12.3 | 51.7 ± 13.0 | 71 ± 8 | 66.2 ± 7.4 | 65 ± 11 | 58 ± 6 | 43.2 (19–67) | 35 ± 13 |
| Age of placebo group | 33.7 ± 11.1 | 50.0 ± 14.3 | 72 ± 6 | 64.9 ± 8.2 | 68 ± 14 | 55 ± 9 | 49.1 (24–73) | 37 ± 13 |
| Gender of statin group | 36 females, 24 males | 26 females, 6 males | 7 females, 20 males | 13 females, 20 males | 9 females, 15 males | 17 females, 17 males | 17 females, 2 males | 79 females, 33 males |
| Gender of placebo group | 30 females, 3 males | 7 females, 19 males | 12 females, 23 males | 8 females, 13 males | 49 females, 29 males | 15 females, 8 males | 65 females, 43 males |
| Body mass index (BMI) of statin group | NA | 28.1 ± 7.7 | 22 ± 2 | NA | NA | NA | 25 ± 5 | 24.4 ± 4.7 |
| Body mass index (BMI) of placebo group | NA | 28.6 ± 7.8 | 23 ± 1 | NA | NA | NA | 24 ± 5 | 26.3 ± 3.3 |
| Type of statin therapy | rosuvastatin | simvastatin | pravastatin | atorvastatin | atorvastatin | atorvastatin | simvastatin | atorvastatin |
| Duration of statin therapy | 6 months | 6 months | 6 months | 6 months | 6 months | 24 weeks | 24 weeks | 24 weeks |
| Baseline 6MWD (m) values in statin group | 416 ± 103 | 422.9 ± 101.4 | NA | NA | 238 ± 124 | 259 ± 94 | 381 ± 69 (198–498) | 355 ± 74 |
| Follow-up 6MWD (m) values in statin group | no increase | no difference | NA | NA | 339 ± 155 | NA | increased by 3.1 ± 3.4 | decreased by 52 (−103–−1)* *increased by 10 (−19–39)** |
| Baseline 6MWD (m) values in placebo group | 415 ± 110 | 418.3 ± 131.7 | NA | NA | 284 ± 100 | 243 ± 120 | 386 ± 110 (120–600) | 346 ± 84 |
| Follow-up 6MWD (m) values in placebo group | no increase | NA | NA | NA | 340 ± 106 | NA | increased by 1.0 ± 57.0 | decreased by 79 (−126–33)* + increased by 50 (31–69)** |
| Baseline values of pulmonary arterial pressure (mmHg) in statin group | 53 ± 16 | 47 ± 8 | 52.7 ± 8.1 | NA | 26 ± 7 | 55.8 ± 10.3 (42–71) | 69 ± 19 |
| Baseline values of pulmonary arterial pressure (mmHg) in placebo group | NA | 47 ± 7 | 51.7 ± 7.9 | NA | 29 ± 7 | 55.7 ± 12.5 (30–81) | 66 ± 20 |

Continued
### Follow-up values of pulmonary arterial pressure (mmHg) in statin group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 40 ± 6    |
| Liu et al.          | 45.4 ± 6.8 | NA       |
| Moosavi et al.      | NA       | decreased by 5.2 mmHg |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 4 (0–7)*; increased by 11 (4–19)**; not changed 0 (−5–4)**

### Follow-up values of pulmonary arterial pressure (mmHg) in placebo group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 46 ± 7    |
| Liu et al.          | 49.1 ± 7.3 | NA       |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 3 (−6)*; increased by 10 (4–16)**; decreased by 5 (−10–0)**

### Baseline values of right atrial pressure (mmHg) in statin group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 8.6 ± 5   |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | 10.3 ± 5  |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Decreased by 5 (−10–0)*

### Baseline values of right atrial pressure (mmHg) in placebo group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | NA        |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 3 (−1–6)*; increased by 10 (4–16)**; decreased by 5 (−10–0)**

### Follow-up values of right atrial pressure in statin group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | NA        |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 3 (2–5)*; increased by 6 (2–9)**; increased by 3 (1–5)**

### Follow-up values of right atrial pressure in placebo group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | NA        |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Decreased by 5 (−10–0)*

### Baseline values of cardiac index (l/m²) in statin group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 4.09 ± 0.49 |
| Liu et al.          | 2.8 ± 0.6 | 2.6 ± 0.65 |
| Moosavi et al.      | 2.4 ± 0.8 | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 0.3 (−0.2–0)*; decreased by 0.3 (−0.5–0)**; not changed 0 (−0.1–0.2)**

### Baseline values of cardiac index (l/m²) in placebo group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 4.33 ± 0.55 |
| Liu et al.          | 2.9 ± 0.7 | 2.5 ± 0.7 |
| Moosavi et al.      | 2.6 ± 1  | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 0.2 (−0.3–0)*; decreased by 0.4 (−0.6–−0.2)**; not changed 0 (−0.3–0.3)**

### Follow-up values of right atrial pressure in statin group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 4.23 ± 0.33 |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Decreased by 0.5 (−0.3–0)*; decreased by 0.5 (−0.4–−0.3)*

### Follow-up values of right atrial pressure in placebo group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 4.26 ± 0.38 |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Decreased by 0.4 (−0.6–−0.2)*; not changed 0 (−0.3–0.3)**

### Baseline values of pulmonary vascular resistance (dyn * s * cm⁻⁵) in statin group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 5.0 ± 2.6  |
| Liu et al.          | 5.0 ± 2.2 | NA        |
| Moosavi et al.      | 1456 ± 699 | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 203 (42–364)*; increased by 440 (119–762)**; increased by 46 (−151–243)**

### Baseline values of pulmonary vascular resistance (dyn * s * cm⁻⁵) in placebo group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | 5.0 ± 2.2  |
| Liu et al.          | 1456 ± 699 | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 287 (132–442)*; increased by 605 (313–897)**; increased by 8 (−150–165)**

### Follow-up values of pulmonary vascular resistance (dyn * s * cm⁻⁵) in statin group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | NA        |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 287 (132–442)*; increased by 605 (313–897)**; increased by 8 (−150–165)**

### Follow-up values of pulmonary vascular resistance (dyn * s * cm⁻⁵) in placebo group

| Study               | Baseline | Follow-up |
|---------------------|----------|-----------|
| Lee et al.          | NA       | NA        |
| Liu et al.          | NA       | NA        |
| Moosavi et al.      | NA       | NA        |
| Reed et al.         | NA       | NA        |
| Wilkins et al.      | NA       | NA        |
| Zeng et al.         | NA       | NA        |

Increased by 287 (132–442)*; increased by 605 (313–897)**; increased by 8 (−150–165)**

### Table 1. Main characteristics of the included studies. Data are presented as mean ± SD and range in brackets. ABBREVIATIONS: 6-MWD – 6 minutes walk distance; COPD – chronic obstructive pulmonary disease; FEV1 – forced expiratory volume in one second % of vital capacity; NYHA - New York Heart Association; PAH – pulmonary arterial hypertension; PAP – pulmonary arterial pressure; PFT - pulmonary function test; WHO – world health organization; *mean change; **change in patients with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorder; ***change in patients with pulmonary arterial hypertension associated with congenital heart disease.
Discussion

To our knowledge, the current systematic review and meta-analysis is the first to evaluate the effects of statins on PAH. Contrary to the findings from some studies18,25, this meta-analysis of 8 studies did not suggest any significant improvement in 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index, and pulmonary vascular resistance by statin therapy. The lack of benefit was robust in sensitivity analysis and the statistical significance was not influenced by any single study included in the meta-analysis.

These findings are of clinical interest, since the use of statins in PAH treatment is thought to be beneficial due to their antiproliferative, anti-inflammatory, and pro-apoptotic pleiotropic effects as well as the ability to restore endothelial vasoactive mediator production26. Various studies linked statin effects with the pathogenesis of pulmonary hypertension and various biomarkers27, through analyzing the relation between statins, endothelin-1 and PAH28,29, statins, asymmetric dimethylarginine and PAH30–32, statins, D-dimers and PAH33,34, statins, von Willebrand factor antigen and PAH35,36 or fibrinogen and PAH37,38. Until now, the results obtained using statins on PAH parameters in different animal models have been contradictory. Some experimental studies suggested that statins might attenuate the development or even regress established experimental PAH by decreasing proliferation and increasing apoptosis of pathological smooth muscle cells in the medial walls and neointima of...
pulmonary arteries and reducing right ventricular hypertrophy\textsuperscript{39,40}. Other experimental studies on murine models reported an inhibition of progression of emphysema and pulmonary hypertension related to tobacco exposure after statin therapy\textsuperscript{41,42}. One experimental study showed that low doses of fluvastatin have beneficial effects on adventitial fibroblasts from chronic hypoxic animals through actions on the Rac1-p38 MAP kinase-signaling pathway\textsuperscript{43}. Another experimental study showed that rosuvastatin improved ischemia-reperfusion injury by decreasing macrophage infiltration and up-regulating endothelial nitric oxide synthase\textsuperscript{44}. In contrast, atorvastatin neither improved survival nor reduced PAH, vascular remodeling and right ventricular hypertrophy in an experimental study on a rat monocrotaline PAH model\textsuperscript{45}. However, some experimental studies reported a decrease of right ventricular (RV) hypertrophy associated with statin therapy in PAH models\textsuperscript{46}, but no study showed a reduction in pulmonary arterial pressure\textsuperscript{47,48}. An experimental study on guinea pigs exposed to cigarette smoking during 6 months showed no effects of simvastatin on small airway remodeling\textsuperscript{49}.

Figure 3. Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of statin therapy on pulmonary arterial pressure (PAH) (Fig. 3A), right atrial pressure (RAP) (Fig. 3B), cardiac index (Fig. 3C), and pulmonary vascular resistance (PVR) (Fig. 3D).
The data on humans from short-term randomized trials are few and contradictory. In an open-label observational trial, simvastatin was successfully used as adjunctive therapy in patients with PAH associated with various pathologies\(^2,3\). In another study, atorvastatin reduced pulmonary artery pressure and raised the migration and adhesion of endothelial progenitor cells (EPCs) in patients with chronic pulmonary heart disease\(^20\). Other studies described a decreased frequency of exacerbations and intubations\(^26\), a reduced decline of pulmonary function\(^33\) and decreased pulmonary pressures associated with improved exercise capacity after statin treatment\(^15\) in patients with chronic obstructive pulmonary diseases. A multicenter propensity score study on 2,363 patients showed for the first time that statins improve survival in PAH patients by decreasing one-year all-cause mortality\(^52\).

Similar to our results obtained in this meta-analysis, and in contrast to previous arguments, another study did not find any effect of statins on 6MWD\(^23\), but the short duration of this trial and background therapy of PAH patients may be potential causes for the lack of effects. Another trial on 220 PAH patients showed no benefit of atorvastatin on cardio-pulmonary hemodynamics, 6MWD and survival at 6 months of treatment\(^24\), suggesting that atorvastatin should not be prescribed as specific treatment in PAH.

Limitations. This meta-analysis has several limitations. First, the studies were relatively small and heterogeneous concerning study design, patients characteristics, major outcomes, PAH etiology and severity. Second, the patients included were classified in various functional classification groups. Third, the positive effects of statins in one study might have been overlapped by lack of effects of statins in the rest of studies since the effects of four statins (rosuvastatin, simvastatin, pravastatin and atorvastatin) were analyzed. Fourth, the patients received supportive drugs such as diuretics, warfarin, and digoxin, which could have influenced the results. The follow-up of the study was relatively short (6 months), so the long-term effects cannot be concluded and it is possible that longer therapy with statin might have been effective. Taking into account the given small sample size and short duration of the included studies, the meta-analysis could not also look at CVD outcomes that would be of the greatest interest. Finally, in the most of included studies PAH was diagnosed mainly based on echocardiography, which is also an important limitation.

In conclusion, the results of this meta-analysis of available studies did not show a statistically significant effect of statin therapy in the improvement of 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary vascular resistance. Additional large, long term and well-designed trials are necessary to investigate the impact of statins for the treatment of PAH including their use as pulmonary vascular antiproliferative agents.

References
1. Galie, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)/Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37, 67–119 (2016).
2. Austin, E. D. & Loyd, J. E. Toward Precision Medicine in Pulmonary Arterial Hypertension. Chest Journal 146, 449–475 (2014).
3. Delcroix, M. & Howard, L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. European Respiratory Review: an Official Journal of the European Respiratory Society 24, 621–629 (2015).
4. Taichman, D. B. et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest Journal 146, 449–475 (2014).
5. Sinha, N. et al. Can echocardiographically estimated pulmonary arterial elastance be a non-invasive predictor of pulmonary vascular resistance? Arch Med Sci 10, 692–700 (2014).
6. Sharma, M., Pinnamaneni, S., Aronow, W. S., Jozwik, B. & Frishman, W. H. Existing drugs and agents under investigation for pulmonary arterial hypertension. Cardiology in Review 22, 297–305 (2014).
7. Galie, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)/ Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37, 67–119 (2016).
8. Krishna, R. K. et al. Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: A comprehensive review. Pulmonary Pharmacology & Therapeutics 30, 134–140 (2015).
49. Wright, J. L. & Liu, J. & Tong, T. Estimating the sample mean and standard deviation from the sample size, median and/or interquartile range. BMC Medical Research Methodology 14, 135 (2014).

50. Sutton, A. J., Abrams, K. R. & Jones, D. R. Methods for meta-analysis in medical research. Duval, S. & Tweedie, R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biomетrika 56, 455–463 (2000).

51. Barreto, A., Maeda, N., Soares, R., Cicero, C. & Lopes, A. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. Brazilian Journal of Medical and Biological Research 41, 657–663 (2008).

52. Kawut, S. M. et al. Simvastatin as a treatment for pulmonary hypertension trial. American Journal of Respiratory and Critical Care Medicine 181, 1106–1113 (2010).

53. Zeng, W.-J. et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. European Respiratory Journal 40, 67–74 (2012).

54. Kao, P. N. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127, 1446–1452 (2005).

55. Faul, J. et al. Statins for Treatment of Pulmonary Hypertension, In: Pulmonary Hypertension Contemporary Cardiology™ (eds NicholasS Hill & HarrisonW Farber) Ch. 15, 321–336 (Springer, 2008).

56. Al-Naamani, N. et al. Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society 13, 25–30 (2016).

57. Giannakoulas, G., Mouratoglou, S.-A., Gatzoulis, M. A. & Karvounis, H. Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. a systematic review. International Journal of Cardiology 174, 618–623 (2014).

58. Sahebkar, A. et al. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis 241, 433–442 (2015).

59. Serban, C. A. et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Scientific Reports 5, 9902 (2015).

60. Parkh, R. V. et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS (London, England) 28, 511 (2014).

61. Andersen, C. U. et al. Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease. Respiratory medicine 106, 1749–1753 (2012).

62. Barnes, T. et al. Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis. Rheumatology 51, 1606–1609 (2012).

63. Sahebkar, A. et al. Association between statin use and plasma D-dimer levels. Thrombosis and Haemostasis 114, 546–557 (2015).

64. Sahebkar, A. et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost 115, 520–32 (2016).

65. Lopes, A. A. et al. Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease. Brazilian Journal of Medical and Biological Research 44, 1269–1275 (2011).

66. Kato, F. et al. Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension. Circulation Journal: Official Journal of the Japanese Circulation Society 76, 1754–1761 (2014).

67. Sahebkar, A. et al. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacol Res 103, 236–252, (2016).

68. Lee, J.-H. et al. Simvastatin inhibits cigarette smoking–induced emphysema and pulmonary hypertension in rat lungs. American Journal of Respiratory and Critical Care Medicine 172, 987–993 (2005).

69. Nishimura, T. et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neonitial smooth muscle cells. Circulation 108, 1640–1645 (2003).

70. Girgis, R. E. et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. American Journal of Physiology-Heart and Circulatory Physiology 285, H938–H945 (2003).

71. Girgis, R. E. et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. American Journal of Physiology-Lung Cellular and Molecular Physiology 292, L1105–L1110 (2007).

72. Carlin, C. M. et al. Low-dose iluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. Am J Respir Cell Mol Biol 47, 140–148 (2012).

73. Matsuo, S. et al. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension. J Thorac Cardiovasc Surg 149, 902–909 (2015).

74. McMurtry, M. S. et al. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamycin–atorvastatin-simvastatin study. American Journal of Physiology-Lung Cellular and Molecular Physiology 293, L933–L940 (2007).

75. Murata, T. et al. Statins protect endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 25, 2335–2342 (2005).

76. Sun, X. & Ku, D. D. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. American Journal of Physiology. Heart and Circulatory Physiology 294, H801–809 (2008).

77. Zhao, L. et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. The European Respiratory Journal 34, 948–957 (2009).

78. Wright, J. L. et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 183, 50–58 (2011).
50. Blamoun, A. I. et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. *Int J Clin Pract* 62, 1373–1378 (2008).
51. Alexeeff, S. E., Litonjua, A. A., Sparrow, D., Vokonas, P. S. & Schwartz, J. Statin use reduces decline in lung function: VA Normative Aging Study. *Ann J Respir Crit Care Med* 176, 742–747 (2007).
52. Eshtehardi, P. et al. Statin Therapy Improves Survival in Patients With Severe Pulmonary Hypertension: A Propensity Score Matching Study. *Circulation* 130, A11717 (2014).

Acknowledgements
The meta-analysis has been prepared within Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (www.lbpmcgroup.umed.pl). Four authors (M.R-G., A.G-B., J.R., M.B.) are partially supported by the Healthy Ageing Research Centre project of Medical University of Lodz, Lodz, Poland (REGPOT-2012-2013-1, 7FP).

Author Contributions
M.B. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. M.R.-G. and A.G.-B. contributed to the data acquisition, data analysis and interpretation, and drafting of the manuscript; A.S. contributed to the statistical analysis and the writing and revising of the manuscript; M.C.-S. contributed to the data acquisition, drafting and critical revision of the manuscript; D.P.M., S.U., P.P.T., V.B., G.F.W., G.Y.H.L., J.R. and A.L.C. contributed to critical revision of the manuscript; and M.B. contributed to the study concept and design, drafting of the manuscript, and critical revision and final approval of the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Rysz-Górzynska, M. et al. Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. *Sci. Rep.* 6, 30060; doi: 10.1038/srep30060 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/